Finlands Akademi  
 
 
 
 
 
Finansieringsbeslut
 
Sökande / Kontakt person Elenius, Klaus
Organisation Åbo universitet
Projektets titel Predictive biomarkers for ERBB-targeted cancer drugs
Beslutnr 316796
Beslutsdatum 03.05.2018
Finansierings period 01.09.2018 - 31.08.2022
Finansiering 450 000
   
Beskrivning av projektet
There are several cancer drugs that act by inhibing growth factor receptors in the cancer cells. While these drugs have significantly improved patient outcome, there is still a great clinical need for indicators to identify patients that benefit from the drugs. Better targeting of cancer drugs will lead to avoidance of unnecessary adverse effects, as well as to more cost-effective use of healthcare resources. The goal of our laboratory is to identify novel genetic biomarkers predicting sensitivity to drugs that target one subclass of growth factor receptors, the ERBB receptors. This will be accomplished by using novel screening protocols, recently set up in the laboratory. The findings will be validated by further analyses of cancer cell lines, mouse cancer models, and clinical cancer patient samples. The resulting information is expected to provide better tools to efficiently identify patients benefiting from therapeutics designed to block growth factor receptor signaling.